Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19

- Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: number of Respiratory Failure-Free Days (RFDs) from randomization through Day 28 in the intent-to-treat (ITT) population

- Nezulcitinib demonstrated a favorable trend in improvement when compared to placebo for 28-day all-cause mortality rate (p=0.08)

- In a post-hoc analysis, there was an improvement in mortality (p=0.009) and time to recovery (p=0.02) in patients treated with nezulcitinib who had baseline C-reactive protein (CRP) levels